Organ-on-a-chip Company (OOC) CN Bio has appointed a new Chief Business Officer as part of its commercial business strategy. The company has appointed Dr Paul Brooks to the role, who will be responsible for leading the expansion of its global commercial organisation. Dr Brooks has over 25 years of experience… Read More
Software company Insightful Science has announced it is retiring its brand name and will go forward under the name Dotmatics. The rebrand follows the merger of Insightful Science and Dotmatic in 2021 and the organisation now has a global team of over 800 employees, supporting customers in… Read More
DDW Deputy Editor Reece Armstrong looks at the key points of GSK’s first quarter earnings. UK pharmaceutical company GSK has reported strong financial earnings for the first quarter of 2022. The pharma giant reported total sales in Q1 of £9.8 billion, crediting much of that to… Read More
Listen to this article on the DDW Podcast: Kizoo Technology Capital has a clear aim – to develop drugs that abate or cure age-related diseases. Lu Rahman spoke to owner, Michael Greve to find out more about this exciting work that aims to make age-related therapies affordable for everyone. Read More
Drug development consultancy Boyds has bolstered its clinical trials expertise with the appointment of Caroline Corbett as Director of Clinical Operations. As Director of Clinical Operations at Boyds, Corbett will support Dr Karen O’Hanlon, Vice President of Clinical Operations, with the ongoing growth… Read More
BioXcel Therapeutics has raised $260 million in funding to support the commercial activities of its proprietary, orally dissolving film formulation IGALMI. Previously known as BXCL501, IGALMI is an orally dissolving film formulation of dexmedetomidine indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder… Read More
GlaxoSmithKline (GSK) is to acquire biopharmaceutical company Sierra Oncology in a deal worth £1.5 billion, the company has announced. Sierra Oncology Sierra Oncology is a late-stage company focused on targeted therapies for the treatment of rare forms of cancer. The company’s lead asset, momelotinib, is being… Read More
Biotechnology company CellCentric has strengthened its leadership team with two new appointments. The company has appointed Kris Frese as Director of Cancer Biology, and Andrew Hughes, who joins the Board as a Non-Executive Director. Kris Frese is an experienced cancer biologist who specialises in models of… Read More
South Korea is supporting innovative pharmaceutical companies by revising the health insurance benefits system. The new system of preferential drug pricing, if designed effectively, can boost innovation in the country’s pharmaceutical research, says GlobalData. According to GlobalData, the pharmaceutical market in South Korea is estimated to grow at a… Read More
Andrew Aldridge, Partner at Deepbridge Capital explains why life science sector has shot up the UK investment agenda as vaccinations are rolled out. The past twelve months have showcased the importance of medical developments like never before. Innovation in the life sciences sector has been headline news around the globe and… Read More
Contract Research Organisation (CRO) Veramed has joined a community of global companies using business as a force for good. Veramed, provider of specialist statistics and programming services to biopharmaceutical companies, announced that it has been awarded a B Corporation certification. The certification addresses all parts of a business’ operations, covering… Read More
Today’s episode on the topic of The Business Side of Drug Discovery, covers 3 articles taken from the most recent Fall issue of DDW. These articles are titled: Building the foundations for post COVID-19 R&D, Opportunity Knocks: Why compound screening libraries are worth the investment, and How to achieve data driven R&D at speed… Read More
Several pharmacological treatments for non-alcoholic steatohepatitis (NASH) are expected to be launched in the seven major markets (7MM*) over the next 10 years. It is anticipated that these products can demand higher prices than the current off-label therapies, considering no therapy has been approved for the indication, and drive strong… Read More
By Ibis Sanchez-Serrano and Rathnam Chaguturu Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This article examines the major initiatives being explored at the… Read More
By Dr Jamie Freeman Base editing is a potentially transformative technology for engineering DNA in cells that has the potential to generate knockouts or correct certain errors or mutations in the DNA for applications such as cell or gene therapies. Compared with currently-available gene editing… Read More
By Dr Ross Macdonald Cell-based therapies are being widely recognised for their potential to treat a variety of medical conditions, but they face major obstacles toward commercialisation. Traditionally, they have been difficult and expensive to make in large quantities. Read More
